Tert-butyl 3-(4-bromophenyl)-2,2-dimethylpropanoate | 409097-20-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Tert-butyl 3-(4-bromophenyl)-2,2-dimethylpropanoate
• 英文别名: 3-(4-bromo-phenyl)-2,2-dimethyl-propionic acid tert-butyl ester；tert-butyl 3-(4-bromophenyl)-2,2-dimethylpropionate
• CAS: 409097-20-7
• 化学式: C₁₅H₂₁BrO₂
• 分子量: 313.235
• InChiKey: RMURZULFAFSKOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  344.9±17.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Tert-butyl 3-(4-bromophenyl)-2,2-dimethylpropanoate 在 叔丁基锂 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 正戊烷 为溶剂， 生成 tert-butyl 3-(4-formylphenyl)-2,2-dimethylpropionate
  参考文献：
  名称：

  Propionic acid derivatives

  摘要：

  本申请涉及用于治疗冠心病等疾病的新型有效的PPAR-alpha激活化合物及其制备。

  公开号：

  US20030032671A1
• 作为产物：
  描述：

  叔-丁基异丁酸酯 、 对溴溴苄 以79 %的产率得到Tert-butyl 3-(4-bromophenyl)-2,2-dimethylpropanoate
  参考文献：
  名称：

  NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF

  摘要：

  本发明涉及一种酰胺衍生物化合物，其表现出二酰基甘油酰基转移酶（DGAT）2抑制剂的活性，其化学式表示为（1），一种包含其作为活性成分的药物组合物以及其用途。

  公开号：

  EP4074701A1

文献信息

• Design, synthesis, and biological evaluation of 8-biarylquinolines: A novel class of PDE4 inhibitors
  作者：Michel Gallant、Nathalie Chauret、David Claveau、Stephen Day、Denis Deschênes、Daniel Dubé、Zheng Huang、Patrick Lacombe、France Laliberté、Jean-François Lévesque、Susana Liu、Dwight Macdonald、Joseph Mancini、Paul Masson、Anthony Mastracchio、Donald Nicholson、Deborah A. Nicoll-Griffith、Hélène Perrier、Myriam Salem、Angela Styhler、Robert N. Young、Yves Girard

  DOI：10.1016/j.bmcl.2008.01.004

  日期：2008.2

  of a novel series of 8-biarylquinolines acting as type 4 phosphodiesterase (PDE4) inhibitors is described herein. Prototypical compounds from this series are potent and non-selective inhibitors of the four distinct PDE4 (IC(50)<10 nM) isozymes (A-D). In a human whole blood in vitro assay, they inhibit (IC(50)<0.5 microM) the LPS-induced release of the cytokine TNF-alpha. Optimized inhibitors were evaluated

  本文描述了充当4型磷酸二酯酶（PDE4）抑制剂的一系列新的8-联芳基喹啉系列的结构-活性关系。该系列的典型化合物是四种不同PDE4（IC（50）<10 nM）同功酶（AD）的有效和非选择性抑制剂。在人类全血体外测定中，它们抑制（IC（50）<0.5 microM）LPS诱导的细胞因子TNF-α释放。在清醒的豚鼠中，在卵清蛋白诱导的支气管收缩模型中评估了优化的抑制剂的体内功效。通过在松鼠猴中进行药代动力学研究，评估了它们产生催吐反应的倾向。这项工作已导致鉴定出几种具有优异的体外和体内特性的化合物，其中包括治疗呕吐的良好治疗窗口。
• [EN] 8-(BIARYL) QUINOLINE PDE4 INHIBITORS<br/>[FR] INHIBITEURS DE PDE4 8-(BIARYLE)QUINOLINES
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004000814A1

  公开（公告）日：2003-12-31

  8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues.In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.

  8-(联苯基)喹啉类化合物，其中在8位的联苯基与喹啉基团呈间位关系，是磷酸二酯酶4抑制剂，在治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、嗜酸性肉芽肿、牛皮癣和其他良性或恶性增生性皮肤疾病、内毒素休克、马蹄炎、马胃肠炎、脓毒性休克、溃疡性结肠炎、克罗恩病、心肌和脑再灌注损伤、炎症性关节炎、慢性肾小球肾炎、特应性皮炎、荨麻疹、成人呼吸窘迫综合征、动物慢性阻塞性肺疾病、尿崩症、过敏性鼻炎、过敏性结膜炎、春季结膜炎、动脉再狭窄、动脉粥样硬化、动脉粥样硬化、神经源性炎症、疼痛、咳嗽、类风湿性关节炎、强直性脊柱炎、移植排斥反应、移植物抗宿主病、胃酸过多分泌、细菌、真菌诱导的败血症、病毒诱导的败血症、真菌诱导的脓毒性休克、病毒诱导的脓毒性休克、炎症介导的慢性组织退行性变、细胞因子介导的慢性组织退行性变、骨关节炎、癌症、虚弱、肌肉消耗、抑郁症、记忆障碍、肿瘤生长或癌细胞侵袭正常组织。另一方面，本发明涉及一种增强健康受试者认知能力的方法，包括给予安全的增强认知量的磷酸二酯酶4抑制剂。具体而言，本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断能力的方法，包括给予安全且增强认知量的磷酸二酯酶4抑制剂。
• 8-(Biaryl)quinoline pde4 inhibitors
  申请人：Dube Daniel

  公开号：US20050234238A1

  公开（公告）日：2005-10-20

  8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues. In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.

  8-(联苯基)喹啉中，8位位置的联苯基与喹啉基团呈间位关系，是PDE4抑制剂，可用于治疗哮喘、慢性支气管炎、慢性阻塞性肺疾病、嗜酸性粒细胞肉芽肿、银屑病和其他良性或恶性增生性皮肤疾病、内毒素休克、马蹄疾病、马腹绞痛、败血症休克、溃疡性结肠炎、克罗恩病、心肌和脑再灌注损伤、炎性关节炎、慢性肾小球肾炎、特应性皮炎、荨麻疹、成人呼吸窘迫综合症、动物慢性阻塞性肺疾病、尿崩症、过敏性鼻炎、过敏性结膜炎、春季结膜炎、动脉再狭窄、动脉硬化、神经源性炎症、疼痛、咳嗽、类风湿性关节炎、强直性脊柱炎、移植排斥、移植物抗宿主病、胃酸分泌过多、细菌、真菌引起的败血症、病毒引起的败血症、真菌引起的败血性休克、病毒引起的败血性休克、炎症介导的慢性组织退化、细胞因子介导的慢性组织退化、骨关节炎、癌症、消瘦、肌肉消耗、抑郁症、记忆障碍、肿瘤生长或癌细胞侵袭正常组织。另一方面，本发明还涉及一种增强健康受试者认知能力的方法，包括给予安全的认知增强剂量的磷酸二酯酶-4抑制剂。特别地，本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断能力的方法，包括给予安全的认知增强剂量的磷酸二酯酶-4抑制剂。
• PROPIONSÄUREDERIVATE MIT PPAR-ALPHA AKTIVIERENDEN EIGENSCHAFTEN
  申请人：Bayer Aktiengesellschaft

  公开号：EP1328508A2

  公开（公告）日：2003-07-23
• 8-(BIARYL) QUINOLINE PDE4 INHIBITORS
  申请人：MERCK FROSST CANADA INC.

  公开号：EP1517895A1

  公开（公告）日：2005-03-30